Jun 2026 (Q2 FY26) — Aug 6, 2026
Pulse Biosciences Q2 FY26 — Accelerated Clinical Enrollment and Strengthened Balance Sheet
Read the full callPulse Biosciences (PLSE) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Pulse Biosciences earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.43 | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Operating margin | -5823.0 | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. | |
| Net profit | -24.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$45.59 −1.58% · −$0.73
Performance +164.1% 1Y
1Y: $17.26 on 14 Oct 2025 → $45.59. High $55.2 (15 Sept 2026), low $12.66 (20 Nov 2025).
- Previous close
- $46.32
- 52-week range
- $12.66 – $55.2
- One year
- +163.68%
Overview
- Symbol
- PLSE
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Pulse Biosciences earnings calls (PLSE)
Financials
What the filings say
Net profit, year on year: −29% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 14 | 20 | 18 | 20 | 20 | 19 | 20 | 26 |
| Operating profit | -14 | -20 | -18 | -20 | -20 | -18 | -19 | -25 |
| Operating margin | — | — | — | — | −23682.6% | −6914.0% | −4775.6% | −5823.0% |
| Other income | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -13 | -19 | -17 | -19 | — | — | — | — |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Net profit | -13 | -19 | -17 | -19 | -19 | -17 | -19 | -25 |
| EPS ($ per share) | -0.21 | — | -0.25 | -0.28 | -0.29 | — | -0.27 | -0.36 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -76 | -123 | -173 | -337 | -295 | -337 | -390 | -463 |
| Total liabilities | 4 | 11 | 18 | 15 | 80 | 15 | 18 | 14 |
| Fixed assets | 2 | 3 | 2 | 2 | 2 | 2 | 1 | 1 |
| Investments | 8 | — | 8 | — | — | — | — | — |
| Total assets | 71 | 42 | 41 | 59 | 78 | 59 | 132 | 95 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -24 | -34 | -35 | -54 | -47 | -33 | -36 | -54 |
| Cash from investing | 26 | -10 | 10 | 8 | -0 | -0 | -0 | -0 |
| Cash from financing | 45 | 0 | 31 | 63 | 80 | 16 | 110 | 17 |
| Net cash flow | — | — | 6 | 16 | 33 | -17 | 74 | -37 |
| Capital expenditure | -0 | -1 | -0 | -0 | -0 | -0 | -0 | -0 |
| Free cash flow | -24 | -35 | -36 | -55 | -47 | -33 | -36 | -54 |
Insider filings
20 filings between Feb 9, 2026 and Sep 1, 2026.
Open market
decisions to buy or sellPurchases
$13.50M
6 purchases by 3 insiders
Sales
$2.93M
7 sales by 1 insider
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 7
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| DUGGAN ROBERT W | $13.00M | — | May 11, 2026 |
| Danahy Kevin Patrick | — | $2.93M | Feb 18, 2026 |
| LAVIOLETTE PAUL A | $295.4K | — | May 11, 2026 |
| Teplitsky Liane Rae | $199.9K | — | Sep 1, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Teplitsky Liane Rae Chief Operating Officer | Purchase | 1,001 | $50.0K |
| Aug 31, 2026 | Teplitsky Liane Rae Chief Operating Officer | Purchase | 1,024 | $50.0K |
| Aug 28, 2026 | Teplitsky Liane Rae Chief Operating Officer | Purchase | 1,034 | $50.0K |
| Aug 26, 2026 | Teplitsky Liane Rae Chief Operating Officer | Purchase | 1,036 | $50.0K |
| May 11, 2026 | DUGGAN ROBERT W Director | Purchase | 660,233 | $13.00M |
| May 11, 2026 | LAVIOLETTE PAUL A Chief Executive Officer | Purchase | 15,000 | $295.4K |
| Feb 18, 2026 | Danahy Kevin Patrick Chief Commercial Officer | Sale 10b5-1 plan | 5,000 | $118.2K |
| Feb 18, 2026 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise 10b5-1 plan | 5,000 | $7.7K |
| Feb 17, 2026 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise 10b5-1 plan | 20,000 | $30.6K |
| Feb 17, 2026 | Danahy Kevin Patrick Chief Commercial Officer | Sale 10b5-1 plan | 20,000 | $472.6K |
| Feb 13, 2026 | Danahy Kevin Patrick Chief Commercial Officer | Sale 10b5-1 plan | 20,000 | $470.6K |
| Feb 13, 2026 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise 10b5-1 plan | 20,000 | $30.6K |
| Feb 12, 2026 | Danahy Kevin Patrick Chief Commercial Officer | Sale 10b5-1 plan | 20,000 | $467.4K |
| Feb 12, 2026 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise 10b5-1 plan | 20,000 | $30.6K |
| Feb 11, 2026 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise 10b5-1 plan | 20,000 | $30.6K |
| Feb 11, 2026 | Danahy Kevin Patrick Chief Commercial Officer | Sale 10b5-1 plan | 20,000 | $504.0K |
| Feb 10, 2026 | Danahy Kevin Patrick Chief Commercial Officer | Sale 10b5-1 plan | 20,000 | $470.4K |
| Feb 10, 2026 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise 10b5-1 plan | 20,000 | $30.6K |
| Feb 9, 2026 | Danahy Kevin Patrick Chief Commercial Officer | Sale 10b5-1 plan | 20,000 | $429.0K |
| Feb 9, 2026 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise 10b5-1 plan | 20,000 | $30.6K |
| Oct 2, 2025 | Danahy Kevin Patrick Chief Commercial Officer | Sale 10b5-1 plan | 4,600 | $85.2K |
| Oct 2, 2025 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise 10b5-1 plan | 4,600 | $7.0K |
| Sep 19, 2025 | Danahy Kevin Patrick Chief Commercial Officer | Sale 10b5-1 plan | 400 | $7.4K |
| Sep 19, 2025 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise 10b5-1 plan | 400 | $612 |
| Sep 18, 2025 | Danahy Kevin Patrick Chief Commercial Officer | Sale 10b5-1 plan | 20,000 | $369.8K |
| Sep 18, 2025 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise 10b5-1 plan | 20,000 | $30.6K |
| Sep 17, 2025 | UECKER DARRIN Chief Technology Officer | Option exercise 10b5-1 plan | 61,534 | $246.1K |
| Sep 17, 2025 | UECKER DARRIN Chief Technology Officer | Option exercise 10b5-1 plan | 100,000 | $400.0K |
| Sep 17, 2025 | UECKER DARRIN Chief Technology Officer | Option exercise 10b5-1 plan | 20,000 | $80.0K |
| Sep 17, 2025 | UECKER DARRIN Chief Technology Officer | Sale 10b5-1 plan | 20,000 | $324.2K |
| Sep 16, 2025 | UECKER DARRIN Chief Technology Officer | Option exercise 10b5-1 plan | 25,000 | $100.0K |
| Sep 16, 2025 | UECKER DARRIN Chief Technology Officer | Sale 10b5-1 plan | 25,000 | $407.0K |
| Sep 15, 2025 | UECKER DARRIN Chief Technology Officer | Option exercise 10b5-1 plan | 25,000 | $100.0K |
| Sep 15, 2025 | UECKER DARRIN Chief Technology Officer | Sale 10b5-1 plan | 25,000 | $394.3K |
| Sep 12, 2025 | UECKER DARRIN Chief Technology Officer | Option exercise 10b5-1 plan | 25,000 | $100.0K |
| Sep 12, 2025 | UECKER DARRIN Chief Technology Officer | Sale 10b5-1 plan | 25,000 | $358.0K |
| Sep 11, 2025 | UECKER DARRIN Chief Technology Officer | Sale 10b5-1 plan | 25,000 | $369.5K |
| Sep 11, 2025 | UECKER DARRIN Chief Technology Officer | Option exercise 10b5-1 plan | 25,000 | $100.0K |
| Sep 10, 2025 | DUGGAN ROBERT W Director | Purchase | 34,659 | $508.1K |
| Jun 13, 2025 | UECKER DARRIN Chief Technology Officer | Sale | 15,000 | $239.7K |
| Jun 12, 2025 | UECKER DARRIN Chief Technology Officer | Sale | 15,000 | $246.0K |
| Feb 3, 2025 | Zanganeh Mahkam Director | Option exercised | 30,121 | $331.3K |
| Jan 24, 2025 | Zanganeh Mahkam Director | Option exercised | 30,121 | $331.3K |
| Dec 18, 2024 | DUGGAN ROBERT W Director | Option exercised | 5,187,824 | $57.07M |
| Dec 18, 2024 | DUGGAN ROBERT W Director | Option exercised | 49,312 | $542.4K |
| Dec 18, 2024 | DUGGAN ROBERT W Director | Option exercised | 69,020 | $759.2K |
| Dec 13, 2024 | DUGGAN ROBERT W Director | Purchase | 55,256 | $949.3K |
| Dec 12, 2024 | DUGGAN ROBERT W Director | Purchase | 45,404 | $777.8K |
| Dec 11, 2024 | Barrett Burke Thomas Insider | Sale | 50,000 | $871.0K |
| Dec 11, 2024 | DUGGAN ROBERT W Director | Purchase | 50,000 | $871.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for PULSE BIOSCIENCES, INC.
Free account. Everything above stays public.
Write why you follow PULSE BIOSCIENCES, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading